US2363541A - Detoxicant - Google Patents

Detoxicant Download PDF

Info

Publication number
US2363541A
US2363541A US332986A US33298640A US2363541A US 2363541 A US2363541 A US 2363541A US 332986 A US332986 A US 332986A US 33298640 A US33298640 A US 33298640A US 2363541 A US2363541 A US 2363541A
Authority
US
United States
Prior art keywords
cysteine
atophan
therapeutic
ascorbic acid
toxic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US332986A
Inventor
Gustav J Martin
Marvin R Thompson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
William R Warner and Co Inc
Original Assignee
William R Warner and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by William R Warner and Co Inc filed Critical William R Warner and Co Inc
Priority to US332986A priority Critical patent/US2363541A/en
Application granted granted Critical
Publication of US2363541A publication Critical patent/US2363541A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines

Definitions

  • This invention relates to therapeutic materials of lowered toxicity. More particularly, it relates to therapeutic agents comprising Atophan" and similar compounds in admixture with a material lowering the toxicity thereof.
  • Atophan '(phenylquinoline carboxylic acid) is a drug used in the treatment of rheumatism, gout andsimilar diseases of the human body.
  • the amount of the drug that may be administered is usually less than the amount that would obtain the maximum, or in many cases a desirable, therapeutic effect. This limit is occasioned by the toxic action of the Atophan.”
  • This mixture may then be administered in the same way that Atophan is normally administered, namely, orally, parenterally, rectally, While the cysteine alone or the cysteine and ascorbic acid may be administered to the human body separately from the Atophan," we find it moreconvenient to administer them as a mixture since this assures that the proper amount of both ingredients will be administered at the same time, and also eliminates the necessity for administering two drugs which would be less convenient and might give rise to misunderstanding as to the amount and nature of the drugs described have two characteristics, one,
  • cysteine or an equivalent compound is administered at the same of the Atophan.
  • the inclusion of .ascorbic acid with the cysteine gives somewhat more effective results than cysteine alone or than ascorbic acid alone.
  • the Atophan Upon being taken into the body, the Atophan" or related compound and cysteine or the cysteine and ascorbic acid coact or react to produce a material having the non-toxic, therapeutic effect.
  • the Atophan and ascorbic acid and/or cysteine may be reacted in the-laboratory in a manner similar to the action that takes place in the body in order to provide a single new compound which may be administered to produce the non-toxic therapeutic effect, the ascorbic acid conjugate having the approximate composition C22H1'IO7N, while the cysteine conjugate is represented by CmH'1sO4N2S. Both are hitherto unknown compounds.
  • cysteine or cysteine and ascorbic acid amounts of cysteine or cysteine and ascorbic acid
  • the proportions of the materials are not criti cal, since both cysteine and ascorbic acid are found in and formed fromdietary components and may therefore be viewed as a food for the human body. They may'be taken/into the body in relatively large amounts without any harmful action.
  • the upper limit of the proportion of cysteine in our composition is therefore very high, although as a practical matter, in most instances, there is a maximum amount beyond which en- Very small also obtain improved results, and there is no min; imum below which some improvement is not obtained.
  • the proportions may also vary somewhat depending upon the tolerances and peculiarities of the patient with respect to the Atophan. In general, however, we find a mix- .therapeutic material having superior and advantageous non-toxic properties, as described in the specification and following claims forming a part thereof.
  • a therapeutic agent for usein connection with the treatment of rheumatism, gout and similar ailments including Atop'han for combating said ailments, in association with cysteine and an ascorbic acid to lower the toxicity of said Atophan without materially impairing th therapeutic effect thereof.
  • a therapeutic agent for use in connection with the treatment of rheumatism, gout and similar ailments including Atophan. for combating said ailments, in association with cysteine to lower thetoxicity of said Atophan" without materially impairing, the therapeutic. eflect thereof.
  • a therapeutic agent for use in connection with the treatment of rheumatism, gout and similar ailments comprising a compound selected.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Description

' therapeutic and the other toxic.
as its therapeutic eiiect.
to provide a therapeutic agent comprising in Patented Nov. 28, 1944 pn'roxicnnr Gustav J. Martin. Elmhurst, and Marvin R.
Thompson. Great Neck, N. Y., assignors to William R. Warner & Company, Inc., New York, N. Y., a corporation of Delaware No Drawing. Application May 2, 1940,
Serial No. 332,986
4 Claims.
This invention relates to therapeutic materials of lowered toxicity. More particularly, it relates to therapeutic agents comprising Atophan" and similar compounds in admixture with a material lowering the toxicity thereof.
Atophan" '(phenylquinoline carboxylic acid) is a drug used in the treatment of rheumatism, gout andsimilar diseases of the human body. The amount of the drug that may be administered, however, is usually less than the amount that would obtain the maximum, or in many cases a desirable, therapeutic effect. This limit is occasioned by the toxic action of the Atophan."
It is an object of our invention; to provide a therapeutic agent comprising Atophan, its re lated and similarly acting derivatives and compounds, such as novatophan, and atoquinol, which are non-toxic or of reduced toxicity and which canbe administered in greater amounts in most cases, or at least in the usual amounts without an abjectionable toxic eflect on the hu combination Atophan" and related and similarly acting compounds and derivatives with cysteine and their equivalents, i. e., their precursors and" ascorbic acidin either a dry mixture or in soluetc.
tion. This mixture may then be administered in the same way that Atophan is normally administered, namely, orally, parenterally, rectally, While the cysteine alone or the cysteine and ascorbic acid may be administered to the human body separately from the Atophan," we find it moreconvenient to administer them as a mixture since this assures that the proper amount of both ingredients will be administered at the same time, and also eliminates the necessity for administering two drugs which would be less convenient and might give rise to misunderstanding as to the amount and nature of the drugs described have two characteristics, one,
I It would be relatively simple to modify the drug or the action 01 the drug so as to alter its toxic as well However, it is not a simple matterto alter one of these characteristics without altering the other, i, e., to alter the toxicity without destroying the therapeutic effect.
The action and theory of detoxication has been appreciated heretofore, and in general, a detoxifying material is'thought to combine or coact with the drug in the bod in such a manner as to mask the toxic characteristic while leaving unaltered the structural characteristic of the compound that is responsible for the therapeutic eflect. But the exact action of various materials is little known, and the nature of detoxicants or their action with a particular drug so as not to affect its therapeutic effect cannot be predicted from any available knowledge.
We have discovered that if cysteine or an equivalent compound is administered at the same of the Atophan" is not appreciably interfered with. The inclusion of .ascorbic acid with the cysteine gives somewhat more effective results than cysteine alone or than ascorbic acid alone.
It is a further object of our invention therefore administration.
Upon being taken into the body, the Atophan" or related compound and cysteine or the cysteine and ascorbic acid coact or react to produce a material having the non-toxic, therapeutic effect. If desired, the Atophan and ascorbic acid and/or cysteine may be reacted in the-laboratory in a manner similar to the action that takes place in the body in order to provide a single new compound which may be administered to produce the non-toxic therapeutic effect, the ascorbic acid conjugate having the approximate composition C22H1'IO7N, while the cysteine conjugate is represented by CmH'1sO4N2S. Both are hitherto unknown compounds.
hanced results are not obtained. amounts of cysteine or cysteine and ascorbic acid The proportions of the materials are not criti cal, since both cysteine and ascorbic acid are found in and formed fromdietary components and may therefore be viewed as a food for the human body. They may'be taken/into the body in relatively large amounts without any harmful action. The upper limit of the proportion of cysteine in our composition is therefore very high, although as a practical matter, in most instances, there is a maximum amount beyond which en- Very small also obtain improved results, and there is no min; imum below which some improvement is not obtained. -The proportions may also vary somewhat depending upon the tolerances and peculiarities of the patient with respect to the Atophan. In general, however, we find a mix- .therapeutic material having superior and advantageous non-toxic properties, as described in the specification and following claims forming a part thereof.
We claim:
1. A therapeutic agent for usein connection with the treatment of rheumatism, gout and similar ailments including Atop'han for combating said ailments, in association with cysteine and an ascorbic acid to lower the toxicity of said Atophan without materially impairing th therapeutic effect thereof.
2. A therapeutic agent for use in connection with the treatment of rheumatism, gout and similar ailments including Atophan. for combating said ailments, in association with cysteine to lower thetoxicity of said Atophan" without materially impairing, the therapeutic. eflect thereof.
3.A therapeutic agent for use in connection with the treatment of rheumatism, gout and similar ailments, comprising a compound selected.
from the group consisting of phenylcinchoninic acid and its esters, for combating said ailments,
- in association with cysteine and an ascorbic acid to lower the toxicity oi saidcompound without materially impairing the therapeutic eflect 7 thereof.
.4. A therapeutic agent for use in connection with the treatment 0! rheumatism, gout and simi- GUSTAV J. MARTIN. MARVIN a.- THOMPSON.
US332986A 1940-05-02 1940-05-02 Detoxicant Expired - Lifetime US2363541A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US332986A US2363541A (en) 1940-05-02 1940-05-02 Detoxicant

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US332986A US2363541A (en) 1940-05-02 1940-05-02 Detoxicant

Publications (1)

Publication Number Publication Date
US2363541A true US2363541A (en) 1944-11-28

Family

ID=23300762

Family Applications (1)

Application Number Title Priority Date Filing Date
US332986A Expired - Lifetime US2363541A (en) 1940-05-02 1940-05-02 Detoxicant

Country Status (1)

Country Link
US (1) US2363541A (en)

Similar Documents

Publication Publication Date Title
Selye et al. Conditioning by corticoids for the production of cardiac lesions with noradrenaline
US2363541A (en) Detoxicant
US4002758A (en) Medicament which is utilizable in ophthalmology
US2376795A (en) Sulphapyridine composition of low toxicity
US2027722A (en) Therapeutic agent
US1204794A (en) Poison-deterrent.
US2352124A (en) Therapeutic gold compound
US2342879A (en) Detoxicant
US2366742A (en) Detoxicant
US2543674A (en) Blood anticoagulant composition
US3197370A (en) Pyrilamine tannate compositions
US3419571A (en) Method for relieving coronary insufficiency
US2314125A (en) Pharmaceutical composition
US2159214A (en) Double salt of calcium ascorbate and calcium acetylsalicylate and process of making same
US1845486A (en) Synergized codein drugs
US2146083A (en) Preparation for the treatment of diseases in fowl and animals
US3019162A (en) Cinchophen-hydrocortisone topical compositions
US301385A (en) Geoegb mitchell
US2981657A (en) Thyroprotein and strophanthin composition for reducing body weight
US2485501A (en) Chemotherapeutic agents
US1350843A (en) Hair and scalp remedy
DE3219004C1 (en) Pharmaceutical compositions for the treatment of tumours
US2472453A (en) Streptomycin composition of reduced toxicity
Brown et al. Sodium formaldehyde sulphoxylate in experimental acute mercurial poisoning
US1830313A (en) Synergized hypnotic and sedative